Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells

Concepción Fernández-Rodríguez, Antonio Salar, Alfons Navarro, Eva Gimeno, Silvia Pairet, Laura Camacho, Mariana Ferraro, Sergi Serrano, Carles Besses, Beatriz Bellosillo, Blanca Sanchez-Gonzalez

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Abstract

© 2015 © 2015 Informa UK, Ltd. Current standard-of-care therapy for diffuse large B-cell lymphoma (DLBCL) results in up to 40% of patients who either relapse or develop refractory disease. In this setting, further therapeutic improvements are needed. This study analyzed the in vitro effects of the combination of bendamustine with the histone deacetylase inhibitor vorinostat in DLBCL cells. This combination enhanced histone acetylation and double strand DNA breaks resulting in an additive to synergistic cytotoxic effect in both ABC-and GCB-type DLBCL cells, independently of their TP53 mutational status. These results support the rationale for considering bendamustine and vorinostat combination as a novel approach in DLBCL treatment.
Original languageEnglish
Pages (from-to)692-699
JournalLeukemia and Lymphoma
Volume57
Issue number3
DOIs
Publication statusPublished - 3 Mar 2016

Keywords

  • Bendamustine
  • Diffuse large B-cell lymphoma
  • Histone deacetylase inhibitor
  • TP53
  • Vorinostat

Fingerprint

Dive into the research topics of 'Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells'. Together they form a unique fingerprint.

Cite this